跳至主要内容
临床试验/EUCTR2015-004406-42-ES
EUCTR2015-004406-42-ES进行中(未招募)1 期

CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNITY AFTER THYMOGLOBULIN TREATMENT.

FIBICO0 个研究点目标入组 150 人开始时间: 2015年11月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
FIBICO
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • CMV-seropositive kidney transplant,
  • CD8 + T cell immunity specific pretransplant CMV (CMV-reactive
  • Quantiferon pretraspante)
  • > 18 years (adult)
  • Receiving induction therapy with Thymoglobulin
  • Receiving prophylaxis with valganciclovir.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 150
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Multivisceral transplants including kidney-pancreas
  • HIV-infected patients
  • Patients who can not comply with the monitoring protocol

研究者

发起方
FIBICO

相似试验